Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Ovarian Neoplasms 20Breast Neoplasms 11Prostatic Neoplasms 10Fallopian Tube Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Pancreatic Neoplasms 6Triple Negative Breast Neoplasms 4Endometrial Neoplasms 4Lung Neoplasms 3Head and Neck Neoplasms 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Biliary Tract Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1Sarcoma 1SCLC,Extensive Stage 1Recurrence 1Rectal Neoplasms 1Prostate Adenocarcinoma 1Penile Neoplasms 1

Interventions

enzalutamide 10Prednisone 6Docetaxel 6Abiraterone Acetate 4darolutamide 3olaparib 2niraparib 2abiraterone 2Pluvicto 2Nivolumab 2zimberelimab 1xentuzumab 1sacituzumab govitecan 1radium Ra 223 dichloride 1quemliclustat 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1TVB-2640 1Rosuvastatin Calcium 1Pioglitazone 1Omeprazole 1JNJ-64619178 1JNJ-64264681 1Ipilimumab 1Gonadotropin-Releasing Hormone 1Dexamethasone 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × niraparib × 1 year × Clear all
NCT03431350 2026-05-11

QUEST

Janssen Research & Development, LLC

Phase 2 Active not recruiting
136 enrolled 29 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03748641 2026-05-08

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡